Search

Diflucortolone valerate 0.1% in cream form was investigated in 50 patients with various inflammatory dermatoses. The results were very good in 82% of the cases, good in 8% and moderate in 10%.

The authors investigated the therapeutic effect of diflucortolone valerate as an ointment in 40 patients with inflammatory dermatoses of various etiology. They described the antiphlogistic and antipruritic effect of the preparation as excellent and practically devoid of any side effects and cosmetic problems.

Five hundred and seventy-five patients with various steroid-responsive dermatoses were studied for up to six weeks in eighty-eight separate general practices using a new topical corticosteroid. Temetex (diflucortolone valerate 0-1%). It was concluded that Temetex is both effective and well tolerated in a wide variety of conditions, especially eczema and psoriasis. It was also shown that a large-scale general practice trial can be carried out efficiently with a very high compliance rate.

Diflucortolone valerate was clinically investigated as a fatty ointment in 30 dermatological patients. Although this form of application is a special presentation for the treatment of very dry dermatoses, patients with not so dry and weeping dermatoses were also treated in this trial, the object being to include the role played by the vehicle in the results of therapy. Very good to good results were achieved in 80% of the cases treated, while the result was observed to be poor in only 10% of the cases. This latter percentage is comprised for the greater part of patients who had previously been treated with other corticoids and of patients with weeping dermatoses.

The object of the present study was to investigate the clinical efficacy of Nerisona Fatty Ointment in very dry skin conditions. A total of 37 patients, most of them with chronic dermatoses, was treated. Either very good or good results were achieved in 83.8% of the cases. The side effects observed were very slight.

The efficacy and tolerance of 0.1% diflucortolone valerate (Nerisona) in cream, ointment and fatty ointment formulations were investigated in a study in which no control preparations were used. The study was conducted in 657 children over a period of three weeks. The results were compared with those of a trial with the same design conducted with 4,878 adults. Our observations were mainly concentrated on the two groups eczema/dermatitis and neurodermatitis (atopic dermatitis). Nearly 90% of the children taking part in the study exhibited these clinical pictures. By far the best therapeutic results were obtained in neurodermatitis. There was only one therapy failure among 198 patients (99.5%). Overall the results obtained in children were markedly better than those recorded for adults.

Nerisone cream (diflucortolon valerate 0.1%) has been clinically compared with fluocinolon-acetate on a double blind basis. The trial was carried out on 30 patients. The author comments that the results, in spite of some slight casuisties, appear to indicate a certain superiority of Nerisone cream when compared with the competitor's preparation.

59 patients with various skin disorders - most of them in the acute stage - were treated in this trial. The topical investigational preparation was a cream containing 0.1% diflucortolone valerate. The results confirmed that the preparation has a quick-acting and effective antipruritic and antiphlogistic action. The results achieved were good or very good in 91.52% of cases and moderate in 8.47%. No side effects were observed.

Diflucortolone valerate 0.1% (Nerisona), a new topical corticoid, was clinically investigated in ointment form in 51 patients suffering from neither weeping nor very dry allergic and inflammatory skin diseases. The results obtained were good, improvement being observed in 92.1% of the treated cases. The cosmetic properties of the preparation were excellent. No local or systemic side effects were observed.

The aim of the study was to compare the therapeutic effect of the new corticoid, diflucortolone valerate, with the effect of fluocinolone acetonide. The study was conducted as a randomised double-blind trial in 60 patients with various dermatoses. The results were good in 89% of the cases treated with diflucortolone valerate fatty ointment, while the same result was achieved in only 63.5% of the cases treated with fluocinolone acetonide ointment. No side effects were observed during the use of diflucortolone valerate fatty ointment, while local side effects occurred in 2 cases during the use of fluocinolone acetonide ointment.

Diflucortolone valerate 0.1% (investigational number SH K 183 MB) in the form of a cream was clinically investigated in 41 patients with dermatological disorders. All the patients had been treated previously with other topical preparations, but without success. Complete healing or distinct improvement of the objective and subjective symptoms of the disorders was achieved in 100% of the cases treated with the investigational preparation. No side effects were observed at all.

Bibliographic review of all the published cases of granuloma gluteale infantum and study of the second observation in Argentina. In this case there was a previous Leiner's erythrodermia treated with fluorinatec corticoid creams. The typical lesions appeared suddenly. The authors made a histopathologic study and a review of the pathogenetic theories on this dermatose. In the observation of authors the lesion disappeared in spite of persistence with the treatment with fluorinated corticoid creams, one of the causes of this dermatose according to some authors.

A new topical corticosteroid: fluocortin-butylester, was employed in 11 eczematous children (atopic and seborrhoeic dermatitis), with a good clinical result. These topical applications involve no significant risk of interference with the pituitary-adrenal function.

50 patients with weeping dermatoses were treated with the investigational preparation SH K 183 MB - Nerisona Cream. Very good or good results were achieved in 90% of the cases. No systemic or topical side effects were observed. The cream was assessed as being very good in respect of its cosmetic properties.

Butyl 6alpha-fluoro-11beta-hydroxy-3,20-dioxo-16alpha-methyl-1,4-pregnadien-21-oate (fluocortin butylester, Vaspit) is a recently developed corticosteroid, its distinguishing properties being that it is non-embryotoxic and has practially no systemic effects. In the course of 6 multicentre studies fluocortin butylester was tested in the forms of cream, ointment and fatty ointment in a comparison with corresponding formulations containing fluocortolone (Ultralan) caproate or pivalate, or hydrocortisone acetate. The total study population comprised 1705 patients with various dermal disorders. The results of these double-blind contralateral studies permit the conclusion that the efficacy of the Vaspit preparations ranges between those of fluocortolone and hydrocortisone acetate. Considering the risks involved with local corticosteroid therapy in children the development of a local corticosteroid with the properties of fluocortin butylester must be acknowledged as an advance.

Diflucortolone valerate 0.1% in the form of a cream - Nerisona Cream - was investigated in various dermatological diseases. Very good results were achieved in 68.7% of the total of 64 treated cases, good results in 18.8%, moderate results in 9.4% and poor results in 3.1% of the cases. The patients assessed the cosmetic properties of Nerisona Cream as excellent. No side effects were observed.

The antiinflammatory efficacy of butyl 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate (fluocortin butylester, Vaspit) as a 0,75% ointment was tested in comparison with 1% hydrocortisone acetate ointment in the model of the pyrexal erythema. Fluocortin butylester appeared to be significantly superior to hydrocortisone acetate.

Diflucortolone valerate was administered to 35 psoriatic patients of both sexes in 0.3% concentration as a W/O emulsion in comparison with various commercially available preparations to study its action in the psoriasis plaque test according to Scholtz and Dumas. The study showed the test substance to be equipotent with the halcinonide, clobetasol-17-propionate and desoximetasone preparations and significantly superior to those containing betamethasone-17,21-dipropionate, betamethasone-17-valerate and fluocinonide.

The object of the present study was to investigate the clinical efficacy of Nerisona fatty ointment in very skin conditions. A total of 37 patients, most of them with chronic dermatoses, was treated. Either very good or good results were achieved in 100% of the cases. The side effects observed were very slight.

A 0.1% diflucortolone valerate ointment was investigated in a randomised double-blind contralateral comparison against a 0.2% flumethasone ointment in 52 selected patients with neither weeping nor very dry dermatoses. The results are presented and commented on according to indications.

The clinical efficacy of diflucortolone valerate as a fatty ointment was investigated in 65 patients with very dry dermatoses. The results were very positive, being excellent in atopic eczema, neurodermatitis and atopic cheilitis. No side effects were observed.

Bi-Nerisone cream and a control preparation, also in the form of a cream, have been clinically tested on 343 patients by means of a double blind study. Equilvalent results were obtained without registering any significant statistical differences, a finding, however, proving to be of great importance as Bi-Nerisone only contains two active substances (Diflucortolone valerat + Chlorquinaldol), whereas the control preparation contains a total of four (Betamethasone valerate + Gentamycin + Tolnaftate + Clioquinol).

The investigational preparation Nerisona Cream (diflucortolone valerate 0.1%, investigational no. SH K 183 MB) was used in 47 patients with various inflammatory or pruriginous dermatoses. Either very good or good results were achieved in 89.3% of the cases. Nearly all the patients thought highly of the cosmetic properties of the preparation. No side effects were observed.

We report the results of a controlled double blind assay of treatment in 51 dermatologic cases, with a new steroid cream (diflucortolone) and an already known one (flumetasone). The diflucortolone valerate was significantly better than the flumetasone pivalate in the treatment of 16 cases of psoriasis, 33 eczemas and two cases of lichên planus.

A 36-year-old man suffered from diarrhoea for some weeks and was treated with Salazosulphapyridie and Fluocortulon when he developed a transient myopia combined with an angle closure glaucoma. The refraction of his mild hyperopic eyes (+0,5 dpt) changed to -5,5 dpt and the intraocular pressure increased to 40 mm Hg in the right and 42 mm Hg in the left eye. Accommodation and pupillary reflexes were normal. Ultrasonic examination showed an increased axial diameter and a forward shifting of the lens. The resulting flattening of the anterior chamber induced the angle closure glaucoma. All symptoms disappeared within a week after the administration of Fluocortulon had been discontinued.

The new corticosteroid diflucortolone valerate was clinically investigated in an international, multi-centre trial by a total of 162 dermatologists in 22 countries in more than 6,285 patients with inflammatory and allergic skin diseases. Depending on the condition of the skin, diflucortolone valerate was applied as a cream, ointment or fatty ointment at a concentration of 0.1%. Most of the patients treated with the cream displayed weeping skin conditions. The ointment was used mainly in patients with neither weeping nor very dry skin conditions, while the fatty ointment was employed mainly in very dry processes. After the exclusion of invalid record forms, 5,578 cases remained for computer evaluation. The results confirm that the success rate in local corticoid therapy can be improved by adapting the base to the respective skin condition. The forms investigated were found to be highly effective preparations with excellent skin tolerance. They can be placed on a par with today's leading topical corticoid preparations.

6alpha,9-Difluor-11beta-hydroxy-16alpha-methyl-21-valeryloxy-1,4-pregnadiene-3,20-dione (diflucortolone valerate, Nerisona) 0.1% as a cream, ointment and fatty ointment was investigated in a double-blind contralateral design in 925 patients in comparison to fluocortolone (Ultralan), fluocortolone caproate and fluocortolone pivalate in three concurrently performed studies. The results of the contralateral study show Nerisona cream and ointment to be more effective (P less than 0.01) than Ultralan. The fatty ointment was also superior, but the difference was statistically significant (P less than 0.05) only in the indication psoriasis. No differences could be established in the less sensitive absolute assessment. The therapeutic success rate of 76-92% according to strict criteria-only complete healing and distinct improvement were counted as a success-clearly demonstrates the efficacy of the preparations. The local side effects recorded-mainly irritation and burning- were of a mild nature.